Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

Study Purpose

The purpose of this study is to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 50 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Able to understand and communicate with the investigator, willing and capable to comply with all study procedures, and provide written signed and dated informed consent (personally or by a witness) before any assessment is performed - Aged 18 to 40 years inclusive - New-onset plaque psoriasis with appearance of the first psoriasis plaques within the last 12 months before randomization and naïve to any systemic treatment and phototherapy (Arms A1, A2 and Arm B1) - Chronic plaque psoriasis with appearance of the first psoriasis symptoms 5 years or longer and intolerance or inadequate response to phototherapy or any systemic treatment including biologicals, except for IL-17A inhibitors (Arm C1 and Arm C2) - Moderate to severe plaque psoriasis defined at screening and baseline by PASI ≥ 10, and body surface area (BSA) ≥ 10%, and investigator's global assessment (IGA mod 2011) ≥ 3

Exclusion Criteria:

- Forms of psoriasis other than plaque-type (e.g., pustular, erythrodermic, guttate, light sensitive, and drug induced) - Ongoing use of prohibited treatments - Previous treatment with phototherapy or any systemic treatment - Pregnant or nursing (lactating) women - Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during the Treatment Epoch or longer if required by locally-approved prescribing information (e.g., 20 weeks in the EU)

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03020199
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 4
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Novartis Pharmaceuticals
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Argentina, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Germany, Hungary, Norway, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Plaque Psoriasis
Additional Details

The overall study population (Main Study and Mechanistic Sub-study) will consist of a total of 205 male and female patients aged between 18 and 40 years inclusive. Main Study The Main Study will be conducted in patients with new-onset moderate to severe plaque psoriasis not previously treated with any systemic treatment or phototherapy. A total of 160 patients will be randomized to Arm A1 or Arm B1 in approximately 50 sites worldwide. Since a maximum screening failure rate of 20% is expected, approximately 200 patients will be screened. Mechanistic Sub-study Any patient who consents can participate in the Mechanistic Sub-study. Patients with new-onset plaque psoriasis will be randomized to Arm A1b, Arm A2, or Arm B1b, those with chronic plaque psoriasis will be randomized to Arm C1 and Arm C2 (15 patients each). For Arm A1b or Arm B1b, the first 15 patients will be included on a first come first serve basis. Safety assessments :Physical examination, Vital signs, Height and body weight, Laboratory evaluations (hematology, clinical chemistry, high-sensitivity C-reactive protein), Electrocardiogram, Pregnancy, Adverse events Data Analysis The primary efficacy variable is the proportion of patients who achieve PASI 90 at Week 52. The analysis for the primary objective will be based on the full analysis set. For the primary analysis, the following hypothesis testing will be performed: H01: psec = pnbUVB versus HA1: psec ≠ pnbUVB The primary analysis method for PASI 90 response at Week 52 will use an exact logistic regression model with treatment as an explanatory variable and baseline PASI score as covariate. The key secondary variable is the proportion of all randomized patients who achieve PASI 90 at Week 104. In order to reduce selection bias, all patients who do not achieve PASI 90 at Week 52 will also be included in the analysis at Week 104 using the PASI improvement obtained at Week 104 only. For the key secondary analysis, the following hypothesis testing will be performed: H02: p*sec = p*nbUVB versus HA2: p*sec ≠ p*nbUVB

Arms & Interventions

Arms

Experimental: A1

80 patients (65 in Arm A1a and 15 in Arm A1b) with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 48 inclusive.

Active Comparator: B1

80 patients (65 in Arm B1a and 15 in Arm B1b) with new-onset psoriasis will receive 1 or 2 cycles of nb-UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 will not receive a second treatment cycle).Only during the first 4 weeks of each cycle, nb-UVB treatment should be applied in combination with topical calcipotriol 50 μg/g and betamethasone 0.5 mg/g.

Experimental: A2

secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)

Experimental: C1

secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 48 inclusive (last dose administered at Week 48)

Experimental: C2

secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)

Interventions

Biological: - Secukinumab

Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL.

Radiation: - nbUVB

Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application will be performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face is recommended

Biological: - Secukinumab

Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL

Biological: - Secukinumab

Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL

Biological: - Secukinumab

Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL

Drug: - Calcipotriol

Its a topical treatment for Psoriasis. the concentration it is used is 50mcg/g

Drug: - Betamethasone

this is topical cream which is used in 0.5mg/g concentration

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina

Status

Active, not recruiting

Address

Novartis Investigative Site

Ciudad Autonoma de Bs As, Buenos Aires, 1181

Novartis Investigative Site, Buenos Aires, Argentina

Status

Active, not recruiting

Address

Novartis Investigative Site

Buenos Aires, , C1425DKG

Novartis Investigative Site, Pleven, Bulgaria

Status

Active, not recruiting

Address

Novartis Investigative Site

Pleven, , 5800

Novartis Investigative Site, Plovdiv, Bulgaria

Status

Completed

Address

Novartis Investigative Site

Plovdiv, , 4002

Novartis Investigative Site, Sofia, Bulgaria

Status

Active, not recruiting

Address

Novartis Investigative Site

Sofia, , 1407

Novartis Investigative Site, Sofia, Bulgaria

Status

Completed

Address

Novartis Investigative Site

Sofia, , 1431

Novartis Investigative Site, Sofia, Bulgaria

Status

Active, not recruiting

Address

Novartis Investigative Site

Sofia, , 1632

Novartis Investigative Site, Surrey, British Columbia, Canada

Status

Withdrawn

Address

Novartis Investigative Site

Surrey, British Columbia, V3V 0C6

Novartis Investigative Site, Halifax, Nova Scotia, Canada

Status

Recruiting

Address

Novartis Investigative Site

Halifax, Nova Scotia, B3H 1Z2

Novartis Investigative Site, Markham, Ontario, Canada

Status

Active, not recruiting

Address

Novartis Investigative Site

Markham, Ontario, L3P 1X2

Novartis Investigative Site, Sudbury, Ontario, Canada

Status

Active, not recruiting

Address

Novartis Investigative Site

Sudbury, Ontario, P3C 1X8

Novartis Investigative Site, Toronto, Ontario, Canada

Status

Withdrawn

Address

Novartis Investigative Site

Toronto, Ontario, M3H 5Y8

Novartis Investigative Site, Brno, Czechia

Status

Withdrawn

Address

Novartis Investigative Site

Brno, , 656 91

Novartis Investigative Site, Pardubice, Czechia

Status

Withdrawn

Address

Novartis Investigative Site

Pardubice, , 532 03

Novartis Investigative Site, Aarhus, Denmark

Status

Active, not recruiting

Address

Novartis Investigative Site

Aarhus, , 8000

Novartis Investigative Site, Hellerup, Denmark

Status

Withdrawn

Address

Novartis Investigative Site

Hellerup, , 2900

Novartis Investigative Site, Tallinn, Estonia

Status

Completed

Address

Novartis Investigative Site

Tallinn, , 10138

Novartis Investigative Site, Tallinn, Estonia

Status

Active, not recruiting

Address

Novartis Investigative Site

Tallinn, , 13419

Novartis Investigative Site, Tartu, Estonia

Status

Active, not recruiting

Address

Novartis Investigative Site

Tartu, , 51014

Novartis Investigative Site, Tampere, Finland

Status

Active, not recruiting

Address

Novartis Investigative Site

Tampere, , 33100

Novartis Investigative Site, Turku, Finland

Status

Active, not recruiting

Address

Novartis Investigative Site

Turku, , FIN-20100

Novartis Investigative Site, Bad Bentheim, Germany

Status

Recruiting

Address

Novartis Investigative Site

Bad Bentheim, , 48455

Novartis Investigative Site, Berlin, Germany

Status

Recruiting

Address

Novartis Investigative Site

Berlin, , 10789

Novartis Investigative Site, Berlin, Germany

Status

Recruiting

Address

Novartis Investigative Site

Berlin, , 13353

Novartis Investigative Site, Erlangen, Germany

Status

Active, not recruiting

Address

Novartis Investigative Site

Erlangen, , 91054

Novartis Investigative Site, Frankfurt, Germany

Status

Active, not recruiting

Address

Novartis Investigative Site

Frankfurt, , 60590

Novartis Investigative Site, Lubeck, Germany

Status

Recruiting

Address

Novartis Investigative Site

Lubeck, , 23538

Novartis Investigative Site, Potsdam, Germany

Status

Recruiting

Address

Novartis Investigative Site

Potsdam, , 14467

Novartis Investigative Site, Quedlinburg, Germany

Status

Recruiting

Address

Novartis Investigative Site

Quedlinburg, , 06484

Novartis Investigative Site, Budapest, Hungary

Status

Withdrawn

Address

Novartis Investigative Site

Budapest, , 1137

Novartis Investigative Site, Gyor, Hungary

Status

Withdrawn

Address

Novartis Investigative Site

Gyor, , H-9023

Novartis Investigative Site, Nyíregyháza, Hungary

Status

Active, not recruiting

Address

Novartis Investigative Site

Nyíregyháza, , 4400

Novartis Investigative Site, Szolnok, Hungary

Status

Active, not recruiting

Address

Novartis Investigative Site

Szolnok, , 5000

Novartis Investigative Site, Bergen, Norway

Status

Withdrawn

Address

Novartis Investigative Site

Bergen, , NO-5021

Novartis Investigative Site, Oslo, Norway

Status

Withdrawn

Address

Novartis Investigative Site

Oslo, , N-0372

Novartis Investigative Site, Tromsø, Norway

Status

Withdrawn

Address

Novartis Investigative Site

Tromsø, , N-9038

Novartis Investigative Site, Trondheim, Norway

Status

Withdrawn

Address

Novartis Investigative Site

Trondheim, , N-7006

Novartis Investigative Site, Bialystok, Poland

Status

Active, not recruiting

Address

Novartis Investigative Site

Bialystok, , 15-879

Novartis Investigative Site, Bydgoszcz, Poland

Status

Active, not recruiting

Address

Novartis Investigative Site

Bydgoszcz, , 85-094

Novartis Investigative Site, Gdansk, Poland

Status

Recruiting

Address

Novartis Investigative Site

Gdansk, , 80 952

Novartis Investigative Site, Gdansk, Poland

Status

Active, not recruiting

Address

Novartis Investigative Site

Gdansk, , 80-803

Novartis Investigative Site, Krakow, Poland

Status

Active, not recruiting

Address

Novartis Investigative Site

Krakow, , 31-070

Novartis Investigative Site, Lodz, Poland

Status

Active, not recruiting

Address

Novartis Investigative Site

Lodz, , 90-436

Novartis Investigative Site, Lodz, Poland

Status

Active, not recruiting

Address

Novartis Investigative Site

Lodz, , 90-647

Novartis Investigative Site, Lublin, Poland

Status

Recruiting

Address

Novartis Investigative Site

Lublin, , 20-079

Novartis Investigative Site, Iasi, Romania

Status

Withdrawn

Address

Novartis Investigative Site

Iasi, , 700401

Novartis Investigative Site, Barcelona, Cataluna, Spain

Status

Active, not recruiting

Address

Novartis Investigative Site

Barcelona, Cataluna, 08036

Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain

Status

Active, not recruiting

Address

Novartis Investigative Site

Alicante, Comunidad Valenciana, 03010

Novartis Investigative Site, Alcorcon, Madrid, Spain

Status

Completed

Address

Novartis Investigative Site

Alcorcon, Madrid, 28922

Novartis Investigative Site, Badalona, Spain

Status

Completed

Address

Novartis Investigative Site

Badalona, , 08916

Novartis Investigative Site, Barcelona, Spain

Status

Active, not recruiting

Address

Novartis Investigative Site

Barcelona, , 08003

Novartis Investigative Site, Barcelona, Spain

Status

Recruiting

Address

Novartis Investigative Site

Barcelona, , 08025

Novartis Investigative Site, Las Palmas de Gran Canaria, Spain

Status

Completed

Address

Novartis Investigative Site

Las Palmas de Gran Canaria, , 35010

Novartis Investigative Site, Madird, Spain

Status

Active, not recruiting

Address

Novartis Investigative Site

Madird, , 28041

Novartis Investigative Site, Madrid, Spain

Status

Completed

Address

Novartis Investigative Site

Madrid, , 28006

Novartis Investigative Site, Madrid, Spain

Status

Completed

Address

Novartis Investigative Site

Madrid, , 28031

Novartis Investigative Site, Valencia, Spain

Status

Completed

Address

Novartis Investigative Site

Valencia, , 46014

Novartis Investigative Site, Goethenburg, Sweden

Status

Active, not recruiting

Address

Novartis Investigative Site

Goethenburg, ,

Novartis Investigative Site, Malmo, Sweden

Status

Completed

Address

Novartis Investigative Site

Malmo, , 214 28

Novartis Investigative Site, Stockholm, Sweden

Status

Withdrawn

Address

Novartis Investigative Site

Stockholm, , 17176

Novartis Investigative Site, Geneve, Switzerland

Status

Withdrawn

Address

Novartis Investigative Site

Geneve, , 1205

Novartis Investigative Site, Lausanne, Switzerland

Status

Active, not recruiting

Address

Novartis Investigative Site

Lausanne, , CH-1011

Novartis Investigative Site, Zuerich, Switzerland

Status

Withdrawn

Address

Novartis Investigative Site

Zuerich, , 8091

Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom

Status

Active, not recruiting

Address

Novartis Investigative Site

Bradford, West Yorkshire, BD5 0NA

Novartis Investigative Site, Leeds, West Yorkshire, United Kingdom

Status

Active, not recruiting

Address

Novartis Investigative Site

Leeds, West Yorkshire, LS7 4SA

Novartis Investigative Site, London, United Kingdom

Status

Active, not recruiting

Address

Novartis Investigative Site

London, , SE1 9RT

Novartis Investigative Site, Salford, United Kingdom

Status

Completed

Address

Novartis Investigative Site

Salford, , M6 8HD

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.